The U.S. Food and Drug Administration granted priority review to Pfizer Inc.’s supplemental biologics license application for HYMPAVZI (marstacimab) on February 6, 2026. The decision expands the drug’s approved use to include patients with hemophilia A or B who are six years of age or older and have developed inhibitors, as well as pediatric patients aged six to eleven who do not have inhibitors.
Priority review signals that the FDA expects HYMPAVZI to offer a significant therapeutic advantage. The agency has set a PDUFA action date for the second quarter of 2026, which could accelerate the drug’s market entry and the start of revenue generation for Pfizer’s hemophilia portfolio.
Pfizer’s hemophilia business has been a key component of its specialty portfolio. In 2025 the company reported a 2% year‑over‑year decline in overall operational revenue to $62.6 billion, but excluding COVID‑19 products revenue grew 6%. HYMPAVZI is currently approved for patients 12 and older without inhibitors; the expanded indication will broaden the addressable market to include younger patients and those with inhibitors, potentially adding several thousand new patients worldwide and increasing the portfolio’s revenue potential.
The expanded indication positions HYMPAVZI against a rapidly evolving competitive landscape that now includes gene therapies and other non‑factor treatments. By targeting tissue factor pathway inhibitor (TFPI), HYMPAVZI offers a non‑factor prophylactic approach and would be the first such therapy for children 6‑11 with hemophilia B, giving Pfizer a differentiated product in a niche that is underserved by existing factor replacement therapies.
Michael Vincent, M.D., Ph.D., Pfizer’s Chief Inflammation & Immunology Officer, said, “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors, which neutralize factor replacement therapies and render them ineffective. Based on the findings in the BASIS clinical trial program and if approved, we believe HYMPAVZI has the potential to become a transformative option for these patients that have limited or burdensome treatment options today.”
The expanded indication could strengthen Pfizer’s hemophilia portfolio and contribute to the company’s 2026 guidance of $59.5 billion to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS. While the exact contribution of HYMPAVZI to these figures is not yet disclosed, the drug’s broader patient base is expected to add a new revenue stream in a high‑margin specialty market.
Pfizer’s hemophilia strategy faces headwinds, including the discontinuation of its gene therapy candidate Beqvez in February 2025 and increasing competition from other non‑factor therapies. However, HYMPAVZI’s unique mechanism and expanded pediatric indication provide a competitive advantage that could offset these challenges and reinforce Pfizer’s position in the specialty market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.